Shire plans to exit cancer drug development through a deal to sell its oncology unit to a French company, Servier, for $2.4 billion cash. Dublin, Ireland-based Shire (NASDAQ: SHPG), which operates a U.S. headquarters in Lexington, MA, says the deal helps it tighten its rare disease drug focus. Meanwhile, privately held Servier says adding Shire’s […]
Original Article: Shire is Selling Cancer Business for $2.4B to Focus on Rare Disease